Neuro-immune-endocrine mechanisms with poor adherence to aromatase inhibitor therapy in breast cancer

Neuro-immune-endocrine mechanisms with poor adherence to aromatase inhibitor therapy in breast cancer

As the most commonly used endocrine therapy regimen for patients with hormone receptor-positive (HR+) breast cancer (BC) at present, aromatase inhibitors (AIs) reduce the risk of localized and distant recurrence, contralateral BC and secondary cancer, and prolong disease-free survival. Clinical data...

Full description

Bibliographic Details
Main Authors:	Li Huifang, Gao Jie, Feng Yi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-12-01
Series:	Frontiers in Oncology
Subjects:	aromatase inhibitors breast cancer neuro-immune-endocrine adherence stress
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.1054086/full

Similar Items

Identifying determinants of adherence to adjuvant endocrine therapy following breast cancer: A systematic review of reviews
by: Adam Todd, et al.
Published: (2024-02-01)

Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients
by: Roberta Rosso, et al.
Published: (2023-01-01)

Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
by: Butani D, et al.
Published: (2021-11-01)

What influences aromatase inhibitor continuation intention among breast cancer survivors?
by: Young Kyung Seo, et al.
Published: (2021-03-01)

Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trialResearch in context
by: Vivianne C.G. Tjan-Heijnen, et al.
Published: (2023-04-01)

ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor–Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy
by: Tomás Reinert, et al.
Published: (2020-04-01)

An Exemestane Derivative, Oxymestane-D1, as a New Multi-Target Steroidal Aromatase Inhibitor for Estrogen Receptor-Positive (ER<sup>+</sup>) Breast Cancer: Effects on Sensitive and Resistant Cell Lines
by: Cristina Amaral, et al.
Published: (2023-01-01)

Improving medication adherence with adjuvant aromatase inhibitor in women with breast cancer: A randomised controlled trial to evaluate the effect of short message service (SMS) reminder
by: Eng Hooi Tan, et al.
Published: (2020-10-01)

Aromatase inhibitors: the journey from the state of the art to clinical open questions
by: Daniele Generali, et al.
Published: (2023-12-01)

Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management
by: Tara Hyder, et al.
Published: (2021-07-01)

Corrigendum: Aromatase inhibitors: the journey from the state of the art to clinical open questions
by: Daniele Generali, et al.
Published: (2024-01-01)

Extended Adjuvant Endocrine Therapy in Early Breast Cancer Patients—Review and Perspectives
by: Inga Bekes, et al.
Published: (2023-08-01)

The Trinity of Skin: Skin Homeostasis as a Neuro–Endocrine–Immune Organ
by: Rong Jin, et al.
Published: (2022-05-01)

The recent progress of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer therapy
by: Jing Xu, et al.
Published: (2023-07-01)

Aromatase inhibitors in the treatment of endometriosis
by: Radosław Słopień, et al.
Published: (2016-03-01)

Molecular Docking of Aromatase Inhibitors
by: Virapong Prachayasittikul, et al.
Published: (2011-04-01)

Aromatase inhibitor use is a risk factor of carotid plaque presence in endocrine-responsive breast cancer patients
by: Da Hea Seo, et al.
Published: (2019-05-01)

AROMATASE INHIBITORS IN BREAST CANCER THERAPY
by: Hande Karahan, et al.
Published: (2011-04-01)

From Theory to Practice: Bone Health in Women with Early Breast Cancer Treated with Aromatase Inhibitors
by: Leonor Vasconcelos de Matos, et al.
Published: (2021-02-01)

Risk of developing depression from endocrine treatment: A nationwide cohort study of women administered treatment for breast cancer in South Korea
by: Jooyoung Oh, et al.
Published: (2022-09-01)

Improving medication adherence with adjuvant aromatase inhibitor in women with breast cancer: study protocol of a randomised controlled trial to evaluate the effect of short message service (SMS) reminder
by: Yunxin He, et al.
Published: (2018-07-01)

Predictors of adherence and the role of primary non-adherence in antihormonal treatment of breast cancer
by: Ida Dragvoll, et al.
Published: (2022-12-01)

Risks of Aromatase Inhibitor-Related Cardiotoxicity in Patients with Breast Cancer in Asia
by: Wei-Ting Chang, et al.
Published: (2022-01-01)

Lipid changes during endocrine therapy in early-stage breast cancer patients: A real-world study
by: Yuechong Li, et al.
Published: (2024-01-01)

A REGENERATIVE APPROACH TO AN ACUTE EXACERBATION OF HIP PAIN FROM AROMATASE INHIBITOR ASSOCIATED MUSCULOSKELETAL SYNDROME AND AROMATASE-INHIBITOR ARTHRALGIAS
by: Christian Vangeison, et al.
Published: (2022-10-01)

Reconsidering Aromatase for Breast Cancer Treatment: New Roles for an Old Target
by: Jessica Caciolla, et al.
Published: (2020-11-01)

Aromatase Inhibitors and Risk of Metabolic and Cardiovascular Adverse Effects in Breast Cancer Patients—A Systematic Review and Meta-Analysis
by: Kamila Boszkiewicz, et al.
Published: (2022-05-01)

Women’s Beliefs on Early Adherence to Adjuvant Endocrine Therapy for Breast Cancer: A Theory-Based Qualitative Study to Guide the Development of Community Pharmacist Interventions
by: Brittany Humphries, et al.
Published: (2018-06-01)

Association of Endocrine Therapy and Dementia in Women with Breast Cancer
by: Thompson MR, et al.
Published: (2021-04-01)

The Role of Aromatase Inhibitors in Male Prolactinoma
by: Amit Akirov, et al.
Published: (2023-02-01)

Increased Sclerostin Levels after Further Ablation of Remnant Estrogen by Aromatase Inhibitors
by: Wonjin Kim, et al.
Published: (2015-03-01)

Sweet’s Syndrome Induced by Aromatase Inhibitor in the Treatment of Early Breast Cancer
by: Debora Cardoso, et al.
Published: (2020-02-01)

Evaluation of Arthralgia Induced by Aromatase Inhibitor Therapy
by: Gulabi Mese, et al.
Published: (2013-02-01)

Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement
by: Naiba Nabieva, et al.
Published: (2021-11-01)

Effect of denosumab on bone mineral density in Japanese women with osteopenia treated with aromatase inhibitors for breast cancer: subgroup analyses of a Phase II study
by: Nakatsukasa K, et al.
Published: (2018-07-01)

Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study
by: Maria Sund, et al.
Published: (2021-10-01)

Adherence to endocrine therapy among Chinese patients with breast cancer: current status and recommendations for improvement
by: Gao P, et al.
Published: (2018-05-01)

Art of prevention: The importance of dermatologic care when using aromatase inhibitors
by: Sara Behbahani, MD, MS, et al.
Published: (2021-12-01)

Oxylipins as Biomarkers for Aromatase Inhibitor-Induced Arthralgia (AIA) in Breast Cancer Patients
by: Jessica A. Martinez, et al.
Published: (2023-03-01)

Spontaneous regression of a pulmonary arteriovenous malformation during endocrine therapy for breast cancer
by: Kohei Hamamoto, et al.
Published: (2020-01-01)